A neglected pyoderma gangrenosum following COVID-19: A case report

Authors

  • Thamir Kubaisi Department of Dermatology, College of Medicine, University of Anbar; Ramadi, Anbar, Iraq

Keywords:

Pyoderma gangrenosum, dermatological manifestations, prednisolone, Azathioprine

Abstract

COVID-19 infection is related to many skin problems. The pathogenesis is under search, but mainly involves inflammatory and vasculopathic injuries. Pyoderma gangrenosum is an ulcerative sterile inflammatory reaction of the skin. The etiology is unknown in around 50% of the cases. This article reported a 47-years old soldier man with COVID-19 who developed big, very painful, indurated ulcers on his abdomen and another small one at back, treated as pyoderma gangrenosum and established very good improvement on prednisolone and azathioprine. In conclusion, patients of COVID-19 may be at increased risk for emerging pyoderma gangrenosum with significant overlap in disease pathogenesis. Medical doctors should suspect pyoderma gangrenosum in an individual with coronavirus infection who has non-healing ulcers.  

References

Genovese G, Moltrasio C, Berti E, et al. Skin manifestations associated with COVID-19: current knowledge and future perspectives. Dermatology. 2021;237(1):1–12. DOI: 10.1159/000512932

Freeman EE, McMahon DE. Creating dermatology guidelines for COVID-19: The pitfalls of applying evidence-based medicine to an emerging infectious disease. J Am Acad Dermatol. 2020;82:231. DOI: 10.1016/j.jaad.2020.04.002

Charles CA, Bialy TL, Falabella AF, et al. Poor prognosis of arthritis-associated pyoderma gangrenosum. Arch Dermatol. 2004;140(7):861–864. DOI:10.1001/archderm.140.7.861

Syed K, Chaudhary H, Balu B. Pyoderma gangrenosum following COVID-19 infection. J Community Hosp Intern Med Perspect. 2021;11(5):601-603. DOI: 10.1080/20009666.2021.1958492.

Elkhatib R, Giunta G, Hanssens V, et al. Case Report of Two Patients With COVID-19 and Sacral Pressure Injuries Associated with Pyoderma Gangrenosum. Adv Skin Wound Care. 2021;34(8):438-43. DOI: 10.1097/01.ASW.0000744356.54317.c2.

Barry M, AlRajhi A, Aljerian K. Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult. Vaccines (Basel). 2022;10(1):87. DOI: 10.3390/vaccines10010087.

Hung YT, Chung WH, Tsai TF, et al. Haemorrhagic bullous pyoderma gangrenosum following COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2022;36(8):611-3. DOI: 10.1111/jdv.18132.

Maverakis E, Ma C, Shinkai K, et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol. 2018;154(4):461–6. DOI:10.1001/jamadermatol.2017.5980.

Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: a review of 86 patients. Q J Med. 1985;55(217):173-86.

Adisen E, Erduran F, Gürer MA. Pyoderma gangrenosum: a report of 27 patients. Int J Low Extrem Wounds. 2016;15(2):148-54. DOI: 10.1177/1534734616639172

Von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137(6):1000-05.

Mlika RB, Riahi I, Fenniche S, et al. Pyoderma gangrenosum: a report of 21 cases. Int J Dermatol. 2002;41(2):65-8. DOI: 10.1046/j.1365-4362.2002.01329.x

Pereira N, Brites MM, Goncalo M, et al. Pyoderma gangrenosum a review of 24 cases observed over 10 years. Int J Dermatol. 2013;52(8):938-45. DOI: 10.1111/j.1365-4632.2011.05451.x

arzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. Br J Dermatol. 2020;183(3):431–42. DOI: 10.1111/bjd.19264

Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol. 2003;30(2):97–107. DOI: 10.1034/j.1600-0560.2003.00024.x

Chakiri R, Baybay H, Hatimi AE, et al. Clinical and histological patterns and treatment of pyoderma gangrenosum. Pan Afr Med J. 2020;36:59.

DIO: 10.11604/pamj.2020.36.59.12329

Costa S, Bevilacqua D, Cassatella M, et al. Recent advances on the crosstalk between neutrophils and B or T lymphocytes. Immunology. 2019;156(1): 23–32. DIO: org/10.1111/imm.13005.

Russell CD, Unger SA, Walton M, et al. The Human Immune Response to Respiratory Syncytial Virus Infection. Clin Microbiol Rev. 2017;30(2):481-502.

DOI: 10.1128/CMR.00090-16.

Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8. DIO: 10.1093/cid/ciaa248.

Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273-83.

DIO: org/10.1016/j.jaad.2004.10.006.

Downloads

Published

2023-03-05

How to Cite

1.
Kubaisi T. A neglected pyoderma gangrenosum following COVID-19: A case report. J Pak Assoc Dermatol [Internet]. 2023Mar.5 [cited 2024Jun.17];33(1):345-9. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/2064

Issue

Section

Case Reports